Results of two additional trials testing ziltivekimab are expected in the first half of next year.
Novo Nordisk Shares Drop After Drug Candidate Fails in Trial
Results of two additional trials testing ziltivekimab are expected in the first half of next year.
Author: WSJ
Read Original Article